Figure 3.
Bex and Cile effects on tumor STATs phosphorylation and metalloproteinases activity. (A) Graphical representation of the in vivo TCL model and treatment schedule including Veh, Bex with levothyroxine replacement (BexT4+), Cile alone, or Bex with levothyroxine and Cile (BexT4+Cile). (B) p-STAT1 and p-STAT5 determination by flow cytometry in EL4 cells (gated) from tumors of the different groups. (C) Gelatin zymography quantification of MMP2 and MMP9 activities in the tumors. (D) Gelatin zymography quantification of MMP2 and MMP9 activities measured in supernatants of EL4 cells treated for 24 hours with Bex and Cile in the presence of physiological concentrations of THs (n = 5). Cile = 3 μM, Bex = 1.5 μM, T3 = 1 nM, T4 = 100 nM. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001 vs Veh.

Bex and Cile effects on tumor STATs phosphorylation and metalloproteinases activity. (A) Graphical representation of the in vivo TCL model and treatment schedule including Veh, Bex with levothyroxine replacement (BexT4+), Cile alone, or Bex with levothyroxine and Cile (BexT4+Cile). (B) p-STAT1 and p-STAT5 determination by flow cytometry in EL4 cells (gated) from tumors of the different groups. (C) Gelatin zymography quantification of MMP2 and MMP9 activities in the tumors. (D) Gelatin zymography quantification of MMP2 and MMP9 activities measured in supernatants of EL4 cells treated for 24 hours with Bex and Cile in the presence of physiological concentrations of THs (n = 5). Cile = 3 μM, Bex = 1.5 μM, T3 = 1 nM, T4 = 100 nM. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001 vs Veh.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal